Founded in 1999, genOway is a biotechnology company whose goal is to accelerate innovation in medical research by providing researchers and industry with the best research tools. The company specializes in the design, development and commercialization of genetically modified preclinical models, mice, rats and cell lines.

​

With more than 20 years of expertise in custom-designed models, and a technology platform consisting of exclusive worldwide licenses (CRISPR/Cas9, Smash), genOway has developed, as of 2018, a catalog of ready-to-use "humanized" models for immuno-oncology research and immunotherapies.

​

Based in Lyon, France, genOway operates in more than 28 countries in North America, Europe and Asia. Among its customers are 380 institutions including the most prestigious academic research laboratories, and 170 life sciences companies, including 17 of the world's top 20 pharmaceutical companies.

​

genOway is listed on Euronext Paris - Code: ALGEN - ISIN Code: FR0004053510

​

genOway is a member of the WP4 team. The main task within the project is the development of three new genetically modified mouse models: conditional overexpression Knock-in and/or conditional Knock-out models. genOway is in charge of designing and subsequently developing the mouse models from gene cloning to the generation of heterozygous mice validated by PCR and complete sequencing.